Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 4/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 2/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.30 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15074331 | 1.00 | TSHR (0.40) | TSHRCA12CA14SMN1; SMN2CA9 | |
| SCHEMBL15074332 | 1.00 | TSHR (0.40) | TSHRCA12CA14SMN1; SMN2CA9 | |
| SCHEMBL13046566 | 0.80 | CA12 (0.35) | TSHRCA12CA14SMN1; SMN2DPP4 | |
| SCHEMBL13204470 | 0.80 | CA14 (0.58) | TSHRCA12CA14SMN1; SMN2CA9 | |
| SCHEMBL6966533 | 0.80 | CA14 (0.58) | TSHRCA12CA14SMN1; SMN2CA9 | |
| SCHEMBL7274381 | 0.80 | CA14 (0.58) | TSHRCA12CA14SMN1; SMN2CA9 | |
| SCHEMBL790359 | 0.79 | TSHR (0.39) | TSHRCA12CA14SMN1; SMN2CA9 | |
| SCHEMBL790105 | 0.79 | TSHR (0.39) | TSHRCA12CA14SMN1; SMN2CA9 | |
| SCHEMBL790024 | 0.79 | TSHR (0.39) | TSHRCA12CA14SMN1; SMN2CA9 | |
| SCHEMBL16377063 | 0.79 | ALDH1A1 (0.39) | TSHRCA12CA9CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3013340-B9 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN PHARMACEUTICALS INC (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-3013340-B1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN BIOPHARMA INC (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3912984-A1 | 4'-FLUORO-NUCLEOSIDES, 4'-FLUORO-NUCLEOTIDES AND ANALOGS THEREOF FOR THE TREATMENT OF HCV | Janssen BioPharma, Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3797782-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF FOR USE IN THE TREATMENT OF VIRAL INFECTIONS | Janssen BioPharma, Inc. (US) | 2021-03-31 | — | — | EP | disclosed |
| EP-2935303-B1 | 4'-FLUORO-NUCLEOSIDES, 4'-FLUORO-NUCLEOTIDES AND ANALOGS THEREOF FOR THE TREATMENT OF HCV | JANSSEN BIOPHARMA INC (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3160476-B1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF FOR USE IN THE TREATMENT OF VIRAL INFECTION | JANSSEN BIOPHARMA INC (US) | 2020-09-30 | — | — | EP | disclosed |
| EP-3424938-B1 | 4'-AZIDOALKYL-SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN BIOPHARMA INC (US) | 2020-07-22 | — | — | EP | disclosed |
| WO-2020121122-A1 | CYCLOBUTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS | Janssen Biopharma, Inc. (US) | 2020-06-18 | — | — | WO | disclosed |
| WO-2020121123-A2 | CYCLOPENTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS | Janssen Biopharma, Inc. (US) | 2020-06-18 | — | — | WO | disclosed |
| EP-3466959-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen BioPharma, Inc. (US) | 2019-04-10 | — | — | EP | disclosed |
| US-20150005251-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN PHARMACEUTICA NV | 2015-01-01 | — | — | US | disclosed |
| US-8871737-B2 | Substituted nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8772474-B2 | Cyclic nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20140179910-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140179627-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20130252920-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A THIONUCLEOTIDE ANALOG | VERTEX PHARMACEUTICALS INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130165400-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130164261-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071434-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179910-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | TSHR 2960/4885CA12 4861/4885CA14 4746/4885 |
| US-20140179627-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | TSHR 2960/4885CA12 4861/4885CA14 4746/4885 |
| US-20130165400-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, ADAR | TSHR 3355/4885CA12 4763/4885CA14 4206/4885 |
| US-20130164261-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NUDT1, TYMP | TSHR 2346/4885CA12 4862/4885CA14 4763/4885 |
| US-20120071434-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NUDT1, TYMP | TSHR 2346/4885CA12 4862/4885CA14 4763/4885 |
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NTPCR, NUDT1 | TSHR 3446/4885CA12 4443/4885CA14 3689/4885 |
| US-20130252920-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A THIONUCLEOTIDE ANALOG | TYMP, POLN, POLRMT | TSHR 1231/4885CA12 4257/4885CA14 3722/4885 |
| US-20150005251-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, NT5C2 | TSHR 3730/4885CA12 4747/4885CA14 3921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.